After two years, Cell Bio 2022 will return as an in-person meeting December 3-7, 2022, in Washington, DC. We are excited to make it possible for colleagues to reconnect face-to-face, while keeping health and safety paramount. We understand flexibility is also important. In addition to our in-person meeting, limited content will be available on-demand for purchase after the meeting so that all scientists can access the cutting-edge cell biology research that was presented during the in-person meeting.
Stem cells are moving toward the clinic as cellular therapeutics in several indications and are being tested in clinical trials in others. They are also employed to advantage in the discovery of novel therapeutics in several modalities, including physiologically relevant toxicity and drug screening platforms, and lend themselves to other treatment modalities, including gene therapy, and personalized precision medicine.
The goal of this Cell Symposium is to bring together clinicians, academic researchers, and industry and regulatory stakeholders to discuss advances in the field and to champion new ideas to overcome the current challenges across the clinical and translational spectrum of stem–cell-based research and therapy.
The International Research Conference is a federated organization dedicated to bringing together a significant number of diverse scholarly events for presentation within the conference program. Events will run over a span of time during the conference depending on the number and length of the presentations. With its high quality, it provides an exceptional value for students, academics and industry researchers.
International Conference on CRISPR and Gene Editing aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of CRISPR and Gene Editing. It also provides a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of CRISPR and Gene Editing.
There have been tremendous advancements and breakthroughs in cell therapy treatments. Autologous treatments are extremely effective personalized therapies, but have significant medical, cost and commercialization limitations. Allogeneic treatments provide us with an opportunity to expand and extend access to personalized therapies to patients in need, but face efficacy, safety, and process hurdles.
While related, the differences are stark, forcing your company to make unique and critical process and business decisions to ensure your company implements the best technologies to execute the most effective autologous and/or allogeneic cell therapy manufacturing strategy.